Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mike Hernandez

Showing results (81-90 of 96) with videos related to

Pageof 10
Sort By:
JAMA Oncology|January 1, 2016
Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic ChemotherapySarah S Mougalian, Mike Hernandez, Xiudong Lei, et al.
The Journal of Clinical Endocrinology and Metabolism|February 4, 2011
Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignanciesDavid S Hong, Maria E Cabanillas, Jennifer Wheler, et al.
Cancer Prevention Research (Philadelphia, Pa.)|October 13, 2022
Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast CancerParijatham S Thomas, Anisha B Patel, J Jack Lee, et al.
JNCI Cancer Spectrum|November 9, 2023
A phase II clinical trial of frameless, fractionated stereotactic radiation therapy for brain metastasesAmit K Garg, Mike Hernandez, Pamela J Schlembach, et al.
Diagnostics (Basel, Switzerland)|September 13, 2025
Additive Value of EBUS-TBNA for Staging Non-Small Cell Lung Cancer in Patients Evaluated for Stereotactic Body Radiation TherapyJoshua M Boster, S Michael Goertzen, Paula V Sainz, et al.
Journal of Neurosurgery. Spine|August 18, 2018
Implementation of an Enhanced Recovery After Spine Surgery program at a large cancer center: a preliminary analysisRoxana M Grasu, Juan P Cata, Anh Q Dang, et al.
British Journal of Haematology|December 23, 2017
Pre-treatment neutrophil/lymphocyte ratio and platelet/lymphocyte ratio are prognostic of progression in early stage classical Hodgkin lymphomaJay P Reddy, Mike Hernandez, Jillian R Gunther, et al.
International Journal of Radiation Oncology, Biology, Physics|June 30, 2016
Intensity Modulated Proton Therapy Versus Intensity Modulated Photon Radiation Therapy for Oropharyngeal Cancer: First Comparative Results of Patient-Reported OutcomesTerence T Sio, Huei-Kai Lin, Qiuling Shi, et al.
Advances in Radiation Oncology|March 18, 2021
The Reality of Randomized Controlled Trials for Assessing the Benefit of Proton Therapy: Critically Examining the Intent-to-Treat Principle in the Presence of Insurance DenialMike Hernandez, J Jack Lee, Beow Y Yeap, et al.
Cancer Prevention Research (Philadelphia, Pa.)|June 1, 2023
Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In SituAnne E O'Shea, Guy T Clifton, Na Qiao, et al.
Pageof 10

Showing results (81-90 of 96) with videos related to

Sort By:
Pageof 10
JAMA Oncology|January 1, 2016
Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic ChemotherapySarah S Mougalian, Mike Hernandez, Xiudong Lei, et al.
The Journal of Clinical Endocrinology and Metabolism|February 4, 2011
Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignanciesDavid S Hong, Maria E Cabanillas, Jennifer Wheler, et al.
Cancer Prevention Research (Philadelphia, Pa.)|October 13, 2022
Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast CancerParijatham S Thomas, Anisha B Patel, J Jack Lee, et al.
JNCI Cancer Spectrum|November 9, 2023
A phase II clinical trial of frameless, fractionated stereotactic radiation therapy for brain metastasesAmit K Garg, Mike Hernandez, Pamela J Schlembach, et al.
Diagnostics (Basel, Switzerland)|September 13, 2025
Additive Value of EBUS-TBNA for Staging Non-Small Cell Lung Cancer in Patients Evaluated for Stereotactic Body Radiation TherapyJoshua M Boster, S Michael Goertzen, Paula V Sainz, et al.
Journal of Neurosurgery. Spine|August 18, 2018
Implementation of an Enhanced Recovery After Spine Surgery program at a large cancer center: a preliminary analysisRoxana M Grasu, Juan P Cata, Anh Q Dang, et al.
British Journal of Haematology|December 23, 2017
Pre-treatment neutrophil/lymphocyte ratio and platelet/lymphocyte ratio are prognostic of progression in early stage classical Hodgkin lymphomaJay P Reddy, Mike Hernandez, Jillian R Gunther, et al.
International Journal of Radiation Oncology, Biology, Physics|June 30, 2016
Intensity Modulated Proton Therapy Versus Intensity Modulated Photon Radiation Therapy for Oropharyngeal Cancer: First Comparative Results of Patient-Reported OutcomesTerence T Sio, Huei-Kai Lin, Qiuling Shi, et al.
Advances in Radiation Oncology|March 18, 2021
The Reality of Randomized Controlled Trials for Assessing the Benefit of Proton Therapy: Critically Examining the Intent-to-Treat Principle in the Presence of Insurance DenialMike Hernandez, J Jack Lee, Beow Y Yeap, et al.
Cancer Prevention Research (Philadelphia, Pa.)|June 1, 2023
Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In SituAnne E O'Shea, Guy T Clifton, Na Qiao, et al.
Pageof 10